TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21715530

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Duloxetine (120 mg)
Number of subjects: 16
Study: 19228745

Group type: EXPERIMENTAL
Intervention: Peptide vaccine alone (arm A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Peptide vaccine + GM-CSF (arm B)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Peptide vaccine + IFN-alpha2b (arm C)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Peptide vaccine + IFN-alpha2b + GM-CSF (arm D)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Vaccine immune response
Number of subjects: 115

Group type: COMPARATOR
Intervention: No immune response
Number of subjects: 115
Study: 16806095

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12775857

Group type: EXPERIMENTAL
Intervention: NRT plus counselling (6 week course of NRT and 20 minute counselling intervention)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Counselling alone (20 minute intervention with written materials)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Usual care (no additional advice at admission)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: NRT plus counselling
Number of subjects: 274

Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 274

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: NRT plus counselling, Counselling alone, Usual care
Number of subjects: 274
Study: 10684783

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Alcohol (0.34, 0.68, and 1.02 g/kg)
Number of subjects: 87
Study: 9361639

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) including visual examination, finger pads for palpation, and using the 3 middle fingers.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Omitting 1 of the 3 BSE components.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Omitting 2 of the 3 BSE components.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Omitting all 3 BSE components.
Number of subjects: 220
Study: 8364943

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% cream
Number of subjects: 143

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% cream (long-term phase)
Number of subjects: 143
Study: 3313841

Group type: EXPERIMENTAL
Intervention: Aza‐Po
Number of subjects: 64

Group type: COMPARATOR
Intervention: CsA‐Po
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aza‐Po to CsA‐Po
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CsA‐Po to Aza‐Po
Number of subjects: 64
Study: 29897249

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once-daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral semaglutide alone
Number of subjects: 54
Study: 25903686

Group type: EXPERIMENTAL
Intervention: Single debridement (SD) at postoperative week 1
Number of subjects: 62

Group type: COMPARATOR
Intervention: Frequent debridement (FD) at postoperative weeks 1, 2 and 4
Number of subjects: 62
Study: 24495204

Group type: EXPERIMENTAL
Intervention: Couples treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Individuals treatment
Number of subjects: 93
Study: 23539727

Group type: EXPERIMENTAL
Intervention: Desiccated thyroid extract (DTE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Levothyroxine (L-T₄)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neither (no preference)
Number of subjects: 70
Study: 16192761

Group type: EXPERIMENTAL
Intervention: Org 25969 (8 mg/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Org 25969 (0.1-8.0 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12905476

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg every 6 weeks after induction phase)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo followed by Infliximab (12-week crossover)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo followed by Infliximab
Number of subjects: 65
Study: 9797093

Group type: EXPERIMENTAL
Intervention: Doppler blood flow measurements and serum VEGF concentrations measured at various stages of the IVF cycle.
Number of subjects: 107
Study: 7892316

Group type: EXPERIMENTAL
Intervention: Rapid expansion starting 1 week postoperatively on a daily basis; expansion period of 14 days.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Slow expansion starting after 2 weeks, once each week; expansion period of 37 days.
Number of subjects: 28
Study: 2293600

Group type: EXPERIMENTAL
Intervention: Liquid diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Solid diet
Number of subjects: 6
Study: 204624

Group type: EXPERIMENTAL
Intervention: Specialized aftercare clinic
Number of subjects: 30

Group type: COMPARATOR
Intervention: Private psychiatrists
Number of subjects: 30
Study: 29779802

Group type: EXPERIMENTAL
Intervention: Trophic feeds (10‐20 ml/kg/day) starting 4‐6 hours after surgery
Number of subjects: 15

Group type: COMPARATOR
Intervention: NPO (no feeding) for 48 hours after surgery
Number of subjects: 15
Study: 27809219

Group type: EXPERIMENTAL
Intervention: Red meat/refined grain diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dairy/chicken/nuts/whole grain diet
Number of subjects: 51
Study: 24743444

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264
Study: 21749488

Group type: EXPERIMENTAL
Intervention: Teff bread (TB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control bread (CB)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TB+level 2 phytase (TB+P2)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TB+level 1 phytase (TB+P1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Supplement containing 10 mg of ferrous sulphate
Number of subjects: 58
Study: 20008056

Group type: EXPERIMENTAL
Intervention: 25 microg intravaginal misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: 50 microg intravaginal misoprostol
Number of subjects: 120
Study: 18445928

Group type: EXPERIMENTAL
Intervention: Biodegradable membrane coated with 25% doxycycline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Biodegradable membrane alone
Number of subjects: 24
Study: 15777442

Group type: EXPERIMENTAL
Intervention: Oral iron sulphate 80 mg daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 11949775

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (nutritionally balanced amino acid mixtures without tryptophan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (nutritionally balanced amino acid mixtures with tryptophan)
Number of subjects: 0
Study: 10529070

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 114

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 114
Study: 7547822

Group type: EXPERIMENTAL
Intervention: Duodenal infusion of 100 g/l Intralipid (8.36 kJ/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Isotonic saline (9 g NaCl/l)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High-fat meal (fat energy:CHO, 64:18)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-fat meal (fat energy:CHO, 7:76)
Number of subjects: 13
Study: 2389909

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 0.2 mg inhaled three times a day for 2 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo inhaled three times a day for 2 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) treatment withheld after second antigen provocation
Number of subjects: 31
Study: 6108460

Group type: EXPERIMENTAL
Intervention: High-fat breast milk
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-fat breast milk
Number of subjects: 24
Study: 30459103

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28408372

Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 25590523

Group type: EXPERIMENTAL
Intervention: sTM levels at enrollment (highest quartile > 14 ng/mL vs. lowest quartile < 7 ng/mL)
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Syndecan‐1 levels at enrollment (> 240 vs. < 70 ng/mL)
Number of subjects: 1103
Study: 24024727

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (ropinirole 0.25 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21338496

Group type: EXPERIMENTAL
Intervention: Green tea catechins (378 mg/day) and theanine (210 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 19390340

Group type: EXPERIMENTAL
Intervention: PACER (patient-assisted computerized education for recipients of ICDs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 17889242

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITNs)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Control (no ITN use)
Number of subjects: 3500
Study: 15462694

Group type: EXPERIMENTAL
Intervention: U‐Stocking (Venotrain ulcertec) applied for at least eight hours per day for up to 12 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Compression bandages applied for at least eight hours per day for up to 12 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: U‐Stocking
Number of subjects: 134

Group type: COMPARATOR
Intervention: Compression bandages
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: U‐Stocking and Compression bandages
Number of subjects: 134
Study: 11444446

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 56

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56
Study: 9566478

Group type: EXPERIMENTAL
Intervention: Home Detoxification (HD) programme
Number of subjects: 95

Group type: COMPARATOR
Intervention: Minimal Intervention (MI) strategies
Number of subjects: 95
Study: 8040671

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with cisplatin and fluorouracil (5‐FU) followed by radiation therapy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard surgery followed by radiation therapy
Number of subjects: 166
Study: 2494586

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 4880259

Group type: EXPERIMENTAL
Intervention: Hypnosis (monthly sessions and daily autohypnosis for one year)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Breathing exercises (control group)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 252

Group type: COMPARATOR
Intervention: Breathing exercises
Number of subjects: 252

Group type: COMPARATOR
Intervention: Hypnosis and Breathing exercises
Number of subjects: 252
Study: 31740723

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30001225

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 3799
Study: 28000127

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering treatment (target SBP <140 mmHg within 1 hour)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure-lowering treatment (target SBP <180 mmHg)
Number of subjects: 2839
Study: 26362235

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corticosteroid (Steroid) injection
Number of subjects: 60
Study: 23193218

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care (waiting list group)
Number of subjects: 139
Study: 21981559

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study: 18280832

Group type: EXPERIMENTAL
Intervention: Conservative therapy measures (feeding modifications, positioning, tobacco smoke avoidance)
Number of subjects: 40
Study: 16556888

Group type: EXPERIMENTAL
Intervention: Matched related donor (MRD) allogeneic stem cell transplantation (SCT)
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Matched unrelated donor (MUD) allogeneic SCT
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Consolidation/maintenance chemotherapy
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 1508
Study: 12681111

Group type: EXPERIMENTAL
Intervention: Water group (WG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Air group (AG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 11194431

Group type: EXPERIMENTAL
Intervention: Ropivacaine (200 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19
Study: 8791948

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d. plus Clarithromycin 250 mg b.d.
Number of subjects: 120
Study: 1620416

Group type: EXPERIMENTAL
Intervention: Intravenous phosphocreatine administered after induction of anaesthesia, prior to cardiac arrest and after release of aortic cross-clamp
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (control group A)
Number of subjects: 40
Study: 6369215

Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 38

Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 38
Study: 31804383

Group type: EXPERIMENTAL
Intervention: 12-week resistance and aerobic exercise program
Number of subjects: 0
Study: 28831717

Group type: EXPERIMENTAL
Intervention: Brief (3-day) course of levetiracetam (LEV)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Extended treatment (until hospital discharge)
Number of subjects: 84
Study: 25934015

Group type: EXPERIMENTAL
Intervention: External counterpulsation (ECP) treatment, 35 daily 1 hour sessions
Number of subjects: 0
Study: 25135383

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continued Moderate Exercise (CON) for 12 weeks
Number of subjects: 16
Study: 21880037

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Soybean oil (SO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Number of subjects: 8
Study: 20012445

Group type: EXPERIMENTAL
Intervention: Intermittent (INT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continuous (CNT)
Number of subjects: 46
Study: 18062115

Group type: EXPERIMENTAL
Intervention: Essential oil antimicrobial mouthrinse
Number of subjects: 37

Group type: COMPARATOR
Intervention: Negative control mouthrinse
Number of subjects: 37
Study: 16091026

Group type: EXPERIMENTAL
Intervention: IGIV-C
Number of subjects: 172

Group type: COMPARATOR
Intervention: IGIV-SD
Number of subjects: 172
Study: 12043860

Group type: EXPERIMENTAL
Intervention: System B continuous wave of condensation technique followed by Obtura II backfill
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lateral condensation technique
Number of subjects: 60
Study: 9809934

Group type: EXPERIMENTAL
Intervention: Myocardial contrast echocardiography (MCE) using bolus doses of a perfluorocarbon‐filled contrast agent (NC100100)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Harmonic imaging in triggered mode
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: MCE for detection of extensive defects
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combination of wall motion and MCE assessment
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: MCE
Number of subjects: 203
Study: 7661162

Group type: COMPARATOR
Intervention: Triple therapy with bismuth, metronidazole, and tetracycline (BMT) for 1 week
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Triple therapy with sucralfate, metronidazole, and tetracycline (SMT) for 1 week
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (BMT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Control group (SMT)
Number of subjects: 150
Study: 2567768

Group type: EXPERIMENTAL
Intervention: Emulsion followed by rinsing with water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid soap and water
Number of subjects: 0
Study: 769169

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6990320

Group type: EXPERIMENTAL
Intervention: Co-trimazine (sulphadiazine 410 mg and trimethoprim 90 mg 12-hourly)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (sulphamethoxazole 800 mg and trimethoprim 160 mg 12-hourly)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sulphamethizole (1 g 8-hourly)
Number of subjects: 120
Study: 31692308

Group type: EXPERIMENTAL
Intervention: OraQuick rapid test
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Wantai rapid test
Number of subjects: 1408

Group type: COMPARATOR
Intervention: Ortho HCV 3.0 ELISA and Cobas Taqman HCV RNA assays
Number of subjects: 1408
Study: 29492753

Group type: EXPERIMENTAL
Intervention: App+Reminder (weekly reminders to use app)
Number of subjects: 44

Group type: COMPARATOR
Intervention: App (no reminders)
Number of subjects: 44
Study: 25902387

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (IVA) preoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (IVA) within 30 minutes of surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no IVA)
Number of subjects: 150
Study: 24713595

Group type: EXPERIMENTAL
Intervention: Laminar airflow system
Number of subjects: 63

Group type: COMPARATOR
Intervention: Displacement ventilation system
Number of subjects: 63
Study: 22889730

Group type: EXPERIMENTAL
Intervention: Protein supplementation (15 g protein at breakfast and lunch)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 65
Study: 19469426

Group type: EXPERIMENTAL
Intervention: Videotape training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture training group
Number of subjects: 0
Study: 17766770

Group type: EXPERIMENTAL
Intervention: Symptom-focused psychoeducation
Number of subjects: 60
Study: 15244109

Group type: EXPERIMENTAL
Intervention: Stressen (twice daily for 30 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 11784735

Group type: EXPERIMENTAL
Intervention: Bilateral lesions of primary auditory cortex and surrounding areas
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Unilateral lesions of auditory cortex, auditory midbrain, or dorsolateral frontal cortex
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bilateral auditory cortex lesions
Number of subjects: 13
Study: 9698966

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 10172084

Group type: EXPERIMENTAL
Intervention: 100 IU/kg r‐hu EPO
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 200 IU/kg r‐hu EPO
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 2532102

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional insulin injection treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both treatments (CSII and injections)
Number of subjects: 37
Study: 59150

Group type: EXPERIMENTAL
Intervention: Quinine sulphate 320 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31221872

Group type: EXPERIMENTAL
Intervention: Financial incentive (a chance to get shopping points) for increasing daily steps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 27269410

Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose (up to three calculated replacement doses)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Oral ferrous sulphate (150 mg twice daily for six weeks)
Number of subjects: 352
Study: 25831420

Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus (9vHPV) vaccine administered concomitantly with REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Nonconcomitant vaccination group (REPEVAX administered at month 1)
Number of subjects: 1054
Study: 22858889

Group type: EXPERIMENTAL
Intervention: Delivery room temperature set at 25.1±0.6 °C
Number of subjects: 91

Group type: COMPARATOR
Intervention: Delivery room temperature set at 22.5±0.6 °C
Number of subjects: 91
Study: 23724225

Group type: EXPERIMENTAL
Intervention: 400 μg inhaled budesonide
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone orally daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (for prednisolone trial)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (for budesonide trial)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Total cholesterol and high-density lipoprotein
Number of subjects: 37
Study: 19447001

Group type: EXPERIMENTAL
Intervention: Genesis II HF insert
Number of subjects: 100

Group type: COMPARATOR
Intervention: Genesis II PS insert
Number of subjects: 100